News

News 02.11.2023 ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., Nov. 02, 2023 (GLOBE NEWSWIRE) -- Ad hoc announcement pursuant to Art. 53 LR Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN), a clinical-stage biotech company developing a new class of custom-built protein drugs known as DARPin therapeutics, will present preliminary data from its ongoing Phase...

Events, Internal events
Event date: 07.11.2023 When: November 7, 16:00h-17:00h Where: Bio-Technopark, DINAQOR Auditorium, Wagistrasse 25, 8952 Schlieren Federica Cavallo is a Full Professor of Immunology (General Pathology) at the University of Turin, Medical School, and leads the Oncoimmunology Lab at the Department of Molecular Biotechnology and Health Sciences at the University of Turin, Italy. Her pioneering research...

News 27.10.2023 ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., Oct. 26, 2023 (GLOBE NEWSWIRE) -- Ad hoc announcement pursuant to Art. 53 LR: Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN), a clinical-stage biopharmaceutical company developing a class of custom-built protein drugs known as DARPin therapeutics ("Molecular Partners" or the "Company"), today announced corporate highlights and unaudited financial...

Events, External events, News
Event date: 27.08.2024   You can now submit your abstracts for contributed talks, posters, and workshops. The fourth edition of the conference will be held on August 27th and 28th, 2024 at ETH Zurich. It will bring together experts from a variety of disciplines to explore present and future directions in the field of personalized health technologies and...

News 23.10.2023 Schlieren (Zurich Area), Switzerland, and Gaithersburg, MD, USA – October 17, 2023 – ImmunOs Therapeutics AG, a biopharmaceutical company pioneering HLA-based therapeutics to create transformational medicines for cancer and inflammation, today announced a clinical trial collaboration and supply agreement with Merck & Co., Inc., Rahway, NJ, USA to evaluate its...